The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | Identifying and managing taletrectinib-related AEs in ROS+ NSCLC
Geoffrey Liu, MD, University of Toronto, Toronto, Canada, notes that taletrectinib tend to have mild side effects compared to entrectinib and repotrectinib. Gastrointestinal (GI) side effects are the most common, including nausea, vomiting, and diarrhea, which are usually self-limiting and resolve within the first cycle of treatment. A significant proportion of patients may experience low-grade elevations in liver enzymes, which can be monitored and managed with temporary dose interruption or reduction. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
First of all, the TrkB side effects generally are extremely mild. So if you’re used to using entrectinib and repotrectinib, I think clinicians will be pleasantly surprised at how little they have to manage these side effects. The main side effects are twofold. One is that of GI side effects that are related to nausea, vomiting, and diarrhea. These tend to be extremely self-limited...
First of all, the TrkB side effects generally are extremely mild. So if you’re used to using entrectinib and repotrectinib, I think clinicians will be pleasantly surprised at how little they have to manage these side effects. The main side effects are twofold. One is that of GI side effects that are related to nausea, vomiting, and diarrhea. These tend to be extremely self-limited. They tend to occur within the first couple of doses, and the majority of patients will have it resolved well within the first cycle of treatment. And I think the only other issue that is of importance is that a relatively high proportion of patients will have low-grade elevations in liver enzymes. And this generally can just be monitored for the majority of patients. If they do end up increasing to grade 3, temporary dose interruption and dose reduction is a good way to actually manage these patients. Taletrectinib tends to have side effects very early on. Once they’re managed, patients tend to sail all the way through without problems afterwards.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
